Compare Novo Nordisk A/S (NVO) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs ABRDN Physical Gold Shares ETF — how do they compare? Novo Nordisk A/S trades at $46.32 (market cap $207.85B), while ABRDN Physical Gold Shares ETF trades at $42.02. The key difference: Novo Nordisk A/S pays a 3.81% dividend while ABRDN Physical Gold Shares ETF pays none, and ABRDN Physical Gold Shares ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | SGOL | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $63.98 | $51.41 |
52-Week Low | $35.29 | $31.61 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
SGOL, a US-listed gold ETF, trades at $41.91, up 0.26% today, with a bullish technical signal from moving averages but bearish oscillators. Recent news highlights gold's strength amid cooling US inflation and central bank demand, with spot gold reaching $4,438/oz on August 12, 2026. The ETF lacks fundamental ratios like P/E and P/B, as it tracks physical gold, not a company with earnings.
The outlook for SGOL is positive, driven by gold's safe-haven appeal and supportive macroeconomic factors, but risks include Fed policy shifts and gold price volatility. Analyst sentiment is mixed, with technical indicators suggesting caution near overbought levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
